作者: Weihsu Claire Chen , Leaf Huang
DOI: 10.1016/S0065-2660(05)54013-6
关键词:
摘要: Abstract Over the last several years, advances in gene‐based delivery technology arising from field of gene therapy have helped revitalize vaccine development. Genetic vaccination encoding antigen bacteria, virus, and cancer has shown promise protective humoral cellular immunity; however, potential disadvantages naked DNA reduced value approach. To optimize efficiency as well efficacy, non‐viral vector carrier, for example, cationic liposome, particular benefits to circumvent obstacles that both peptide/protein‐ vaccines encountered. Liposome‐mediated provides greater efficacy safer formulation development human use. The success liposome‐based been demonstrated clinical trials further are also progress.